Defactinib - Verastem Oncology
Alternative Names: Defactinib hydrochloride; PF-04554878; PF-4554878; VS-6063Latest Information Update: 04 Nov 2024
At a glance
- Originator Pfizer
- Developer Cancer Research UK; European Network of Gynaecological Oncological Trial Groups; Gynecologic Oncology Group; National Cancer Institute (USA); Pfizer; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University of California, San Diego; University of Utah; Verastem; Verastem Oncology
- Class Amines; Antineoplastics; Benzamides; Fluorinated hydrocarbons; Pyrazines; Pyrimidines; Small molecules; Sulfones
- Mechanism of Action Focal adhesion protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Ovarian cancer
- Phase II Gynaecological cancer; Lymphoma; Malignant-mesothelioma; Multiple myeloma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours; Thyroid cancer; Uveal melanoma
- Phase I/II Fallopian tube cancer; Glioblastoma; Malignant melanoma; Peritoneal cancer
- No development reported Breast cancer; Cancer
Most Recent Events
- 30 Oct 2024 Updated efficacy and adverse events data from a phase II RAMP 201 trial in Ovarian cancer released by Verastem Oncology
- 01 Oct 2024 Phase-I/II clinical trials in Glioblastoma (Late-stage disease, Second-line therapy or greater, Combination therapy) in United Kingdom (PO) (NCT06630260)
- 10 Sep 2024 Verastem anticipates to complete its NDA submission to the US FDA for Ovarian cancer in the second half of 2024